SCHEMBL3593437

SCHEMBL3593437

O=C(O)N1CCC(CO)(c2ccc(F)cc2F)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 3/20 0.44
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PRKAB2 O43741 1/20 0.38
PRKAG1 P54619 1/20 0.38
PRKAA2 P54646 1/20 0.38
PRKAA1 Q13131 1/20 0.38
PRKAG3 Q9UGI9 1/20 0.38
PRKAG2 Q9UGJ0 1/20 0.38
PRKAB1 Q9Y478 1/20 0.38
RAB9A P51151 1/20 0.38
RIPK1 Q13546 1/20 0.37
HCAR3 P49019 1/20 0.36
HCAR2 Q8TDS4 1/20 0.36
GRM5 P41594 1/20 0.36
THRB P10828 1/20 0.36
CYP2C19 P33261 1/20 0.36
HTT P42858 1/20 0.36
SPR P35270 1/20 0.35
HDAC3 O15379 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3600015 0.86 PKM (0.37) CNR1MEN1KMT2ARAB9ARIPK1
SCHEMBL16585059 0.82 BACE1 (0.39) CNR1MEN1KMT2APRKAB2PRKAG1
SCHEMBL13404312 0.81 TACR1 (0.45) HDAC1HDAC2
SCHEMBL3384864 0.81 CNR1 (0.46) CNR1MEN1KMT2AHCAR3HCAR2
SCHEMBL2425390 0.80 HSD11B1 (0.49) ALDH1A1
SCHEMBL3602790 0.76 SLC6A4 (0.43) MEN1KMT2APRKAB2PRKAG1PRKAA2
SCHEMBL5592232 0.75 SLC6A4 (0.41) CNR1PRKAB2PRKAG1PRKAA2PRKAA1
SCHEMBL19030269 0.72 HTR2A (0.47) MEN1KMT2ARIPK1ALDH1A1
SCHEMBL2425376 0.71 HSD11B1 (0.58) MEN1KMT2A
SCHEMBL2778581 0.70 TACR1 (0.45) MEN1KMT2ACYP2C19HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8383821-B2 NK-1 and serotonin transporter inhibitors BRISTOL-MEYERS SQUIBB COMPANY (US) 2013-02-26 US disclosed
US-20100087434-A1 NK-1 and Serotonin Transporter Inhibitors BRISTOL-MYERS SQUIBB COMPANY 2010-04-08 US disclosed
US-20070249607-A1 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-10-25 US disclosed
WO-2007121389-A2 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AS NK-I AND SEROTONIN TRANSPORTER INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087434-A1 NK-1 and Serotonin Transporter Inhibitors SLC6A4, TPH1, SLC6A2 CNR1 370/4885MEN1 654/4885KMT2A 1712/4885
US-20070249607-A1 NK-1 AND SEROTONIN TRANSPORTER INHIBITORS SLC6A4, TPH1, SLC6A2 CNR1 370/4885MEN1 654/4885KMT2A 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.